Amersham Biosciences Advances Analysis of Gene Expression with New CodeLink Human Whole Genome Bioarray.Business Editors/Health/Medical Writers BIOWIRE2K PISCATAWAY, N.J.--(BUSINESS WIRE)--April 5, 2004 55,000 gene targets represented on a single array offer the highest available content Amersham Biosciences, the life sciences business of Amersham (LSE LSE - Language Sensitive Editor :, NYSE NYSE See: New York Stock Exchange :, OSE OSE - Open Systems Environment : AHM AHM Automated Hacking Machines AHM All Hands Meeting AHM Academy for Healthcare Management AHM Atom Heart Mother (Pink Floyd album) AHM Airport Handling Manual AHM Acutely Hazardous Material AHM Anti-Helicopter Mine ), announces the addition of the CodeLink(TM) Human Whole Genome Bioarray to its CodeLink range. The first CodeLink bioarray to offer comprehensive genome-wide expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, of an entire genome is the result of significant advancements made to the CodeLink platform. This new whole genome bioarray enables researchers to significantly discover more by consolidating genome-wide expression profiling into a single chip microarray experiment and increasing the assay sensitivity Assay sensitivity is a property of a clinical trial defined as the ability to distinguish an effective treatment from a less effective or ineffective treatment. Without assay sensitivity, a trial cannot be said to make a distinction between the efficacy of two treatments. . With 54,841 gene targets, the new CodeLink Human Whole Genome Bioarray has the highest content of any commercially available human microarray on a single chip. The majority of this content has been functionally validated to ensure each experiment generates the most biologically meaningful results. The CodeLink Human Whole Genome Bioarray significantly improves productivity by consolidating genome-wide expression profiling into a single microarray experiment. The new bioarray has superior sensitivity to other whole genome arrays, consistently detecting transcripts at a level of 1:900,000 (around 0.3 copies per cell). This enables researchers to detect genes expressed at very low levels. "This new bioarray- manufactured to established Six-Sigma(TM) standards -- addresses researchers' need to assay whole genomes on one chip with ensured accuracy, reproducibility, and sensitivity." said Sam Raha, Vice President of CodeLink at Amersham Biosciences. "It offers the highest throughput of any human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. bioarray in terms of the number of genes assayed per array, both in the coverage of the genome and in the ability to detect very low abundance genes. This will help researchers to study potentially new expression profiles in applications such as drug target identification and biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term. Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery. ." The new bioarray is compatible with the existing CodeLink platform, which includes hardware, reagents and accessories. The CodeLink Expression Analysis Software for data analysis has been improved and upgraded for analysis of whole genome bioarrays. Data generated using the new CodeLink whole genome bioarray is backwards compatible See backward compatible. backwards compatible - backward compatibility with data generated with previous lower density CodeLink human bioarrays so researchers can continue to use existing data as part of future studies. Amersham Biosciences, the life sciences business of Amersham (LSE: NYSE: OSE: AHM), is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences' products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America and Asia. More information about Amersham Biosciences is available at www.amershambiosciences.com. Amersham Biosciences--enabling molecular medicine http://www.amershambiosciences.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion